Premium
Growth‐inhibitory activity of interferon‐beta against human colorectal carcinoma cell lines
Author(s) -
Wong Vicky L. Y.,
Rieman Dave J.,
Aronson Lori,
Dalton Barbara J.,
Greig Russell,
Anzano Mario A.
Publication year - 1989
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910430331
Subject(s) - cell culture , cell growth , polyclonal antibodies , in vitro , fibroblast , cancer research , lymphokine , interferon , medicine , biology , antibody , immunology , endocrinology , microbiology and biotechnology , biochemistry , genetics
Recombinant human interferon beta (rIFN‐β) inhibited in a time‐ and dose‐dependent manner the proliferation of 18/18 human colon carcinoma cell lines in monolayer culture and 8/9 lines in a soft agar assay but had no effect on 4 human fibroblast cell lines. Maximal inhibition of cell proliferation by rIFN‐β required repetitive treatment (every 2 days) with lymphokine (50 units/ml). Furthermore, the inhibitory activity of rIFN‐β was neutralized by polyclonal antibodies against natural IFN‐β. In contrast to rIFN‐β, rIFN‐α was inactive against all colon cell lines tested, and rIFN‐γ, with the exception of HT‐29 cells, was similarly ineffective. These data demonstrate that rIFN‐β is a potent growth inhibitor of colon carcinoma cells in vitro , and suggest that studies on its mechanism of action may lead to a better understanding of the regulation of colon tumor cell proliferation.